Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Nkarta, Inc. director Ali Behbahani reported receiving a stock option grant covering 37,000 shares of common stock. The option has an exercise price of $2.46 per share and expires on June 9, 2036.
All 37,000 shares subject to the option vest 100% on the first to occur of June 10, 2027 or the day immediately before the first annual stockholder meeting after the grant date. The award becomes fully vested earlier if there is a defined change in control of Nkarta or if Behbahani’s service ends due to death or disability. Following this grant, he directly holds options for 37,000 underlying shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Behbahani Ali
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 37,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 37,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 37,000 shares
Exercise price: $2.46 per share
Expiration date: June 9, 2036
+1 more
4 metrics
Option grant size
37,000 shares
Stock Option (right to buy) granted to director Ali Behbahani
Exercise price
$2.46 per share
Conversion or exercise price of the granted stock options
Expiration date
June 9, 2036
Expiration of Behbahani’s stock option grant
Post-grant option holdings
37,000 shares
Total shares underlying options following the transaction
Key Terms
Stock Option (right to buy), change in control, disability, vesting
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
change in control financial
"will become fully vested should a "change in control" of the Issuer occur"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
disability financial
"separation from service with the Issuer due to the Reporting Person's death or "disability""
vesting financial
"All shares subject to the option vest 100% on the first to occur of (i) June 10, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did Nkarta (NKTX) disclose for director Ali Behbahani?
Nkarta disclosed that director Ali Behbahani received a stock option grant for 37,000 shares of common stock. The options were awarded as compensation, not bought on the open market, and are exercisable at $2.46 per share with long-term vesting conditions and a 2036 expiration.
What is the exercise price and expiration date of the Nkarta (NKTX) options granted to Ali Behbahani?
The options have an exercise price of $2.46 per share and expire on June 9, 2036. This means Behbahani can, once vested, purchase shares at $2.46 any time before that expiration date, assuming he continues to meet the award’s service conditions.
When do Ali Behbahani’s Nkarta (NKTX) stock options vest?
All 37,000 option shares vest 100% on the earlier of June 10, 2027 or the day immediately before the first Nkarta annual stockholder meeting after the grant date. The award can also fully vest sooner upon certain change-in-control, death, or disability events.
Do the Nkarta (NKTX) options for Ali Behbahani have accelerated vesting provisions?
Yes. Any unvested portion becomes fully vested upon a qualifying change in control of Nkarta, or if Behbahani’s service ends because of death or disability. These acceleration terms are defined in the applicable award agreement referenced in the Form 4 footnote.